Sensei Biotherapeutics Inc
$ 30.49
4.35%
17 Apr - close price
- Market Cap 40,865,200 USD
- Current Price $ 30.49
- High / Low $ 30.99 / 29.05
- Stock P/E N/A
- Book Value 18.24
- EPS -16.72
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.41 %
- ROE -0.74 %
- 52 Week High 36.76
- 52 Week Low 5.26
About
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, is dedicated to the discovery and development of therapies with an initial focus on cancer treatments. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$32.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-14 | 2025-08-05 | 2025-05-07 | 2025-02-26 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-03 | 2023-05-09 |
| Reported EPS | -3.74 | -3.62 | -3.91 | -0.2725 | -0.2728 | -0.29 | -0.28 | -0.32 | -0.3 | -0.28 | -0.31 | -0.33 |
| Estimated EPS | -4.81 | -0.23 | -0.24 | -0.26 | -0.29 | -0.31 | -0.29 | -0.28 | -0.31 | -0.34 | -0.33 | -0.36 |
| Surprise | 1.07 | -3.39 | -3.67 | -0.0125 | 0.0172 | 0.02 | 0.01 | -0.04 | 0.01 | 0.06 | 0.02 | 0.03 |
| Surprise Percentage | 22.2453% | -1473.913% | -1529.1667% | -4.8077% | 5.931% | 6.4516% | 3.4483% | -14.2857% | 3.2258% | 17.6471% | 6.0606% | 8.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNSE
2026-04-16 22:10:12
Sensei Biotherapeutics' COO, Anand Parikh, is expected to be appointed CEO if certain proposals are approved by shareholders at the upcoming annual meeting on May 16, 2024. The company has nominated new board members and is making leadership changes as part of an optimization to advance its VISTA inhibitor program and extend its cash runway. Current CEO John Celebi will not be standing for re-election.
2026-04-16 20:09:20
Sensei Biotherapeutics (NASDAQ: SNSE) has announced a contingent overhaul of its board and leadership team, tied to stockholder approvals at their June 10, 2026 annual meeting. This includes the conditional resignations of three current directors and the appointment of three new directors, alongside a projected leadership transition with Anand Parikh becoming CEO and Brian Stephenson becoming CFO. The company also adopted a new Severance and Change in Control Plan for executives, offering enhanced benefits for qualifying terminations.
2026-04-16 20:09:20
Sensei Biotherapeutics (NASDAQ: SNSE) is seeking shareholder approval for proposals related to its acquisition of Faeth Therapeutics and a concurrent $200 million private placement. These proposals, including the conversion of Series B Preferred Stock into common stock and an increase in authorized shares, are crucial for the company's future operations and are expected to result in a change of control. Failure to approve these matters could lead to cash settlement obligations and further delays in the integration of the two companies, with significant dilutive effects on existing shareholders.
2026-04-15 20:40:15
Sensei Biotherapeutics (SNSE) filed an amended report detailing the acquisition of Faeth Therapeutics, including audited 2025 and 2024 financial statements for Faeth. The filing highlights Faeth's significant net losses and an auditor's warning about substantial doubt regarding the combined entity's ability to continue as a going concern due to potential cash settlement obligations related to a $200 million PIPE financing in Series B Non-Voting Convertible Preferred Stock. These obligations could arise if Sensei fails to secure timely stockholder approval or deliver common shares upon conversion.
2026-04-14 21:39:11
Sensei Biotherapeutics (SNSE) has granted its Principal Financial and Accounting Officer, Josiah Craver, 80,000 stock options. These options, with an exercise price of $29.89 per share, were granted on April 10, 2026, and will vest over several years, with full vesting by April 10, 2030, subject to continuous service. The grant is a compensation-related acquisition rather than a market trade.
2026-04-14 21:39:11
Sensei Biotherapeutics director Phillip B. Donenberg received a supplemental stock option grant of 23,100 shares of common stock, bringing his total initial director option grant to 25,000 shares in line with the company's amended compensation policy. The options have an exercise price of $29.89 per share, expire on April 9, 2036, and vest in 36 equal monthly installments over three years, fully vesting on April 10, 2029, contingent on his continued service. This grant supplements an earlier 1,900-share grant from February 2026.
